TherapeuticsMD Inc (NASDAQ:TXMD)’s share price was up 6.4% on Friday . The stock traded as high as $6.07 and last traded at $6.02. Approximately 2,747,655 shares were traded during mid-day trading, an increase of 38% from the average daily volume of 1,984,159 shares. The stock had previously closed at $5.66.
Several equities analysts have weighed in on TXMD shares. Cantor Fitzgerald reiterated a “buy” rating and issued a $28.00 target price on shares of TherapeuticsMD in a report on Sunday, January 7th. Zacks Investment Research lowered shares of TherapeuticsMD from a “hold” rating to a “sell” rating in a report on Friday, January 12th. BidaskClub lowered shares of TherapeuticsMD from a “sell” rating to a “strong sell” rating in a report on Wednesday, January 31st. ValuEngine lowered shares of TherapeuticsMD from a “sell” rating to a “strong sell” rating in a report on Friday, March 2nd. Finally, Oppenheimer restated a “buy” rating on shares of TherapeuticsMD in a report on Wednesday, March 21st. Two analysts have rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company’s stock. TherapeuticsMD has a consensus rating of “Buy” and a consensus price target of $14.50.
Get TherapeuticsMD alerts:
The firm has a market capitalization of $1,275.68, a P/E ratio of -16.27 and a beta of 1.34.
TherapeuticsMD (NASDAQ:TXMD) last issued its quarterly earnings data on Thursday, May 3rd. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.01). TherapeuticsMD had a negative return on equity of 63.67% and a negative net margin of 458.49%. The company had revenue of $3.77 million during the quarter, compared to analyst estimates of $4.18 million. During the same quarter in the prior year, the company posted ($0.11) earnings per share. The business’s revenue was down 5.4% compared to the same quarter last year. sell-side analysts expect that TherapeuticsMD Inc will post -0.39 earnings per share for the current fiscal year.
Several hedge funds have recently modified their holdings of TXMD. Wells Fargo & Company MN increased its stake in TherapeuticsMD by 13.6% during the 3rd quarter. Wells Fargo & Company MN now owns 217,820 shares of the company’s stock worth $1,153,000 after buying an additional 26,007 shares during the period. Schwab Charles Investment Management Inc. increased its stake in TherapeuticsMD by 18.4% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 819,043 shares of the company’s stock worth $4,948,000 after buying an additional 127,410 shares during the period. Edge Wealth Management LLC increased its stake in TherapeuticsMD by 2,500.0% during the 4th quarter. Edge Wealth Management LLC now owns 20,800 shares of the company’s stock worth $125,000 after buying an additional 20,000 shares during the period. Greenwood Capital Associates LLC increased its stake in TherapeuticsMD by 25.9% during the 4th quarter. Greenwood Capital Associates LLC now owns 74,268 shares of the company’s stock worth $449,000 after buying an additional 15,300 shares during the period. Finally, Claraphi Advisory Network LLC purchased a new stake in TherapeuticsMD during the 4th quarter worth approximately $275,000. Hedge funds and other institutional investors own 73.41% of the company’s stock.
TherapeuticsMD, Inc is a healthcare company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes.